Phase II study of sorafenib in patients with relapsed or refractory lymphoma

British Journal of Haematology
Anna GuidettiAlessandro M Gianni

Abstract

The safety and activity of the multikinase inhibitor sorafenib were investigated in patients with relapsed or refractory lymphoproliferative disorders who received sorafenib (400 mg) twice daily until disease progression or appearance of significant clinical toxicity. The primary endpoint was overall response rate (ORR). Biomarkers of sorafenib activity were analysed at baseline and during treatment. Thirty patients (median age, 61 years; range, 18-74) received a median of 4 months of therapy. Grade 3-4 toxicities included hand/foot skin reactions (20%), infections (12%), neutropenia (20%) and thrombocytopenia (14%). Two patients achieved complete remission (CR), and two achieved partial remission (PR) for an ORR of 13%. Stable disease (SD) and progressive disease (PD) was observed in 15 (50%) and 11 patients (37%), respectively. The median overall survival (OS) for all patients was 16 months. For patients who achieved CR, PR and SD, the median time to progression and OS was 5 and 24 months, respectively. Compared with patients with PD, responsive patients had significantly higher baseline levels of extracellular signal-regulated kinase phosphorylation and autophagy and presented a significant reduction of these parameters afte...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Feb 1, 2002·Nature Biotechnology·Omar D Perez, Garry P Nolan
Nov 25, 2003·Oncogene·Suzanne CoryJerry M Adams
Sep 3, 2004·Human Pathology·Jeong Hee Cho-VegaL Jeffrey Medeiros
Dec 2, 2004·Nature Reviews. Cancer·Judith S Sebolt-Leopold, Roman Herrera
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigScott H Kaufmann
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Oct 4, 2006·Nature Reviews. Drug Discovery·Scott WilhelmSusan Kelley
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Aug 23, 2007·Nature Reviews. Molecular Cell Biology·Daniel J Klionsky
May 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corrado TarellaAlessandro Rambaldi
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alvaro Moreno-AspitiaEdith A Perez
Dec 5, 2008·The New England Journal of Medicine·Giancarlo Spinzi, Silvia Paggi
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard T KloosManisha H Shah
Apr 18, 2009·Biochimica Et Biophysica Acta·Eugenia MorselliGuido Kroemer
May 5, 2009·Autophagy·David C RubinszteinDaniel J Klionsky
Apr 16, 2010·The New England Journal of Medicine·Georg Lenz, Louis M Staudt
May 18, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Giuseppina NicotraCiro Isidoro
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen K WilliamsonSusan G Urba
Aug 13, 2010·Cell Cycle·Alexandre PuissantPatrick Auberger
Oct 19, 2010·Haematologica·Gautam BorthakurJorge E Cortes
Oct 30, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michele Del VecchioAndrea Anichini
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela MateiMichael J Birrer
Feb 23, 2011·Critical Reviews in Oncology/hematology·Fabio A B SchutzToni K Choueiri

❮ Previous
Next ❯

Citations

May 31, 2014·Cell Death & Disease·T ColasantiE Ortona
Aug 29, 2013·Journal of the American Academy of Dermatology·Courtney J EnsslinMario E Lacouture
Mar 14, 2014·The Journal of Clinical Hypertension·Yan LiBenkang Shi
Aug 1, 2015·Biomarkers in Medicine·Carmelo Carlo-Stella, Armando Santoro
Apr 19, 2015·Biochemical and Biophysical Research Communications·Michael I KoukourakisAlexandra Giatromanolaki
Jul 5, 2016·Frontiers in Pharmacology·Nestor Prieto-DomínguezJosé L Mauriz
Jan 31, 2018·International Journal of Hematology·Han Zhang
Nov 8, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Marina PierdominiciWalter Malorni
Sep 17, 2017·Oncotarget·Lian LiuPei-Yuan Li
Sep 19, 2018·Cancer Chemotherapy and Pharmacology·Lei ZhanBing Wei
May 16, 2020·Frontiers in Pharmacology·Ferda KaleağasıoğluMartin R Berger
Sep 1, 2015·American Journal of Therapeutics·XiongWen YangYingZhang Cheng
Sep 23, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna GuidettiAlessandro M Gianni
Jul 3, 2021·Current Oncology·Ritu ShresthaAparna Jayachandran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms